ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection December 1, 2025 4:15 PM EST
Company Participants
Ted Karkus – Chairman & CEO
Presentation
Operator
Welcome, everyone. This is the ProPhase Labs Webinar. We’ll be getting started in 3 minutes at a quarter after the hour. This is the ProPhase Labs Webinar with RedChip. We’ll be started.
Ted Karkus
Chairman & CEO
Ted Karkus here, CEO of ProPhase Labs. How is that?
Operator
Thank you very much. Let us get started.
Hi. This is Craig with RedChip Companies. Thank you for joining today’s event with ProPhase Labs, which trades on the NASDAQ under the ticker PRPH. With us today, we have Ted Karkus, the Chairman and CEO of ProPhase. We will begin with a brief presentation in a moment, and then we will answer your questions. [Operator Instructions] Before we begin, please allow me to read the safe harbor statement. This call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results along with other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact should also be considered forward-looking statements. Of course, forward-looking statements involve risks and uncertainties. I now turn this webinar over to Ted. Please go ahead.
Ted Karkus
Chairman & CEO
Great. Thank you, Craig, and thank you all for joining. I am going to assume that most of you are new to the story of ProPhase Labs and to me, that’s the approach I’m going. I do other presentations throughout the year usually monthly, where it’s mostly for shareholders that know the company well. But the approach I’m going to take today is going to be
